Can all patients with deep vein thrombosis receive low-molecular-weight heparin in an outpatient setting?

Haemostasis

Volumn 29, Issue SUPPL. 1, 1999, Pages 84-88

  Lindmarker, Per ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Feasibility; Low molecular weight heparin; Outpatient; Venous thromboembolism

Indexed keywords

DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; REVIPARIN;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG TOLERANCE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTPATIENT CARE; PRIORITY JOURNAL; THROMBOEMBOLISM; TREATMENT CONTRAINDICATION;

EID: 0033378611     PISSN: 03010147     EISSN: None     Source Type: Journal    
DOI: 10.1159/000054120     Document Type: Conference Paper

References (16)

1. Hull RD, Raskob GE, Pinco GF, Green D, Trowbridge AA, Elliott CG, Lerner RG, Hall J, Sparling T, Brettell HR: Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximalvein thrombosis. N Engl J Med 1992;326:975-982.
2. Prandoni P, Lensing AWA, Buller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A, ten Cate JW: Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339;441-445.
3. Lindmarker P, Holmstrom M, Granqvist S, Johnson H, Lockneer D: Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994;72: 186-190.
4. Lopaciuk S, Meissner A, Filipecki S, Zawilska K, Sowier J, Ciesielski L, Bielawiec M, Glowinski S, Czestochowska E: Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: A Polish multicenter trial. Thromb Haemost 1992;68:14-18.
5. Luomanmaki K, Grankvist S, Hallert C, Jauro I, Ketola K, Kim HC, Kiviniemi H, Koskivirta H, Sorskog L, Vikko P: A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. J Intern Med 1996; 240:85-92.
6. Fiessinger JN, Lopez-Fernandez M, Gatterer E, Granqvist S, Kher A, Olsson CG: Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost 1996;76:195-199.
7. Duroux P, Beelere A: A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicentre study. Thromb Haemost 1991;65:251-256.
8. Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, Laurent M, Hirsch JL, Ferrari E, Bosson JL, Mottier D, Beau B: A comparison of low-molecular-weight heparin with unfractionatcd heparin for acute pulmonary embolism. N Engl J Med 1997;337:663-669.
9. Blattler W: Ambulatory care for ambulant patients with deep vein thrombosis. J Mal Vasculaires 1991; 16:137-141.
10. Lindmarker P, Holmstrom M: Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group. J Intern Med 1996; 240:395-401.
11. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AGG, Demers C, Kovacs M: A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-681.
12. Koopman MM, Prandoni P, Piovella F, Ockleford PA, Brandjes DPM, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH, Bossuyt PMM, de Haes H, van den Belt AGM, Sagnard L, d'Azemar P, Buller HR: Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The TASMAN Study Group. N Engl J Med 1996;334:682-687.
13. The Columbus Investigators: Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997;337:657-662.
14. Wells PS, Kovacs MJ, Bormanis J, Forgie MA, Goudie D, Morrow B, Kovacs J: Expanding eligibility for outpatient treatment of deep vein thrombosis and pulmonary embolism with low-molecular-weight heparin: A comparison of patient self-injection with homecare injection. Arch Intern Med 1998;158:1809-1812.
15. Grau E, Real E, Pastor E, Viciano V, Aguilo J: Home treatment of deep vein thrombosis: A two-year experience of a single institution. Haematologica 1998;83:438-441.
16. van den Belt AG, Bossuyt PM, Prins MH, Gallus AS, Buller HR: Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis - an economic evaluation. TASMAN Study Group. Thromb Haemost 1998;79:259-263.